• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5050498)   Today's Articles (2397)
For: Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, Soma M, Okamoto H, Oitate M, Arakawa S, Hirai T, Atsumi R, Nakada T, Hayakawa I, Abe Y, Agatsuma T. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res 2016;22:5097-5108. [DOI: 10.1158/1078-0432.ccr-15-2822] [Citation(s) in RCA: 353] [Impact Index Per Article: 39.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2015] [Accepted: 03/20/2016] [Indexed: 12/31/2022]
Number Cited by Other Article(s)
1
Liu X, Cheng J, Tang M, Liao C, Yang Y, Luo M, Xu L, Zhong X, Ma Q, Guo X. Exploring the novel role and mechanistic insights of skeletal muscle relaxant cyclobenzaprine hydrochloride in esophageal squamous cell carcinoma treatment. Eur J Pharm Sci 2025;210:107051. [PMID: 40021097 DOI: 10.1016/j.ejps.2025.107051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2024] [Revised: 02/18/2025] [Accepted: 02/21/2025] [Indexed: 03/03/2025]
2
Peng X, Lan B, Wang J, Li Q, Wang J, Fan Y, Luo Y, Chen S, Mo H, Li L, Sun X, Zhang J, Cai R, Zhang P, Xu B, Ma F. The ideal strategies of antibody‒drug conjugate sequential treatment in HER2-expressing metastatic breast cancer: A multi-center real-world study. Breast 2025;81:104470. [PMID: 40203774 PMCID: PMC12008598 DOI: 10.1016/j.breast.2025.104470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2024] [Revised: 03/22/2025] [Accepted: 04/03/2025] [Indexed: 04/11/2025]  Open
3
Yang C, Zhang C, Huang Y, Zhu X, Jiang J, Zeng Y, Zhang H, Li L, Liu Y, Li Y. Efficacy of disitamab vedotin (RC48) for previously treated human epidermal growth factor receptor 2-positive breast cancer with symptomatic brain metastases: a case report and review of the literature. Anticancer Drugs 2025;36:440-445. [PMID: 40063535 DOI: 10.1097/cad.0000000000001702] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2025]
4
Shen K, Yuan S, Su N, Tang F, Rehim S, Wang H, Guo H, Zhang Y, Wu Y, Wang H. Monotherapy and combination therapy using antibody‑drug conjugates for platinum‑resistant ovarian cancer. Oncol Rep 2025;53:68. [PMID: 40242965 PMCID: PMC12046379 DOI: 10.3892/or.2025.8901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2024] [Accepted: 03/17/2025] [Indexed: 04/18/2025]  Open
5
Song S, Liu Y, Liu J, Tai W. In Silico-Driven THIOMAB Approach for Stable PROTAC Conjugates by Docking Payloads in Antibody Cavities. Bioconjug Chem 2025;36:960-970. [PMID: 40196986 DOI: 10.1021/acs.bioconjchem.4c00588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/09/2025]
6
Rao B, Huo P, Lu J, Huang W. Advances in Targeted Therapy for Brain Metastases in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer: A Focus on ADCs and TKIs. BREAST CANCER (DOVE MEDICAL PRESS) 2025;17:423-432. [PMID: 40416059 PMCID: PMC12102737 DOI: 10.2147/bctt.s503703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 10/30/2024] [Accepted: 04/28/2025] [Indexed: 05/27/2025]
7
Yaghoubi N, Fatemi B, Ahmadi R, Metghalchi Y, Shahrami B, Vaezi M, Rezaei S. Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience. BMC Health Serv Res 2025;25:711. [PMID: 40380283 PMCID: PMC12084944 DOI: 10.1186/s12913-025-12876-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2025] [Accepted: 05/12/2025] [Indexed: 05/19/2025]  Open
8
Miski H, Krupa K, Budzik MP, Deptała A, Badowska-Kozakiewicz A. HER2-Positive Breast Cancer-Current Treatment Management and New Therapeutic Methods for Brain Metastasis. Biomedicines 2025;13:1153. [PMID: 40426980 PMCID: PMC12109299 DOI: 10.3390/biomedicines13051153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2025] [Revised: 04/28/2025] [Accepted: 04/30/2025] [Indexed: 05/29/2025]  Open
9
Yeh R, Pareja F, Shobeiri P, Ross D, Jayaprakasam VS, Razmaria AA, Drago JZ, Mauguen A, Lyashchenko SK, Zeglis BM, Lewis JS, Ulaner GA. Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis. J Nucl Med 2025:jnumed.124.269227. [PMID: 40341092 DOI: 10.2967/jnumed.124.269227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2024] [Accepted: 03/31/2025] [Indexed: 05/10/2025]  Open
10
Bruzzone F, Barigazzi C, Di Muzio A, Tallarico I, Dipasquale A, Losurdo A, Persico P, Navarria P, Pessina F, Santoro A, Simonelli M. Exploring the Role of ADCs in Brain Metastases and Primary Brain Tumors: Insight and Future Directions. Cancers (Basel) 2025;17:1591. [PMID: 40361515 PMCID: PMC12072133 DOI: 10.3390/cancers17091591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2025] [Revised: 04/28/2025] [Accepted: 05/02/2025] [Indexed: 05/15/2025]  Open
11
Lv Y, Cui X, Li T, Liu C, Wang A, Wang T, Zhou X, Li R, Zhang F, Hu Y, Zhang T, Liu Z. Mechanism of action and future perspectives of ADCs in combination with immune checkpoint inhibitors for solid tumors. Clin Exp Med 2025;25:139. [PMID: 40319436 PMCID: PMC12050234 DOI: 10.1007/s10238-025-01655-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2025] [Accepted: 03/26/2025] [Indexed: 05/07/2025]
12
Russo G, Scimone C, Palumbo L, Roscigno G, Sarracino C, Tomaiuolo I, Pisapia P, Pepe F, Rocco D, Gridelli C, Troncone G, Malapelle U. Biologics for novel driver altered non-small cell lung cancer: potential and pitfalls. Crit Rev Oncol Hematol 2025;212:104748. [PMID: 40324663 DOI: 10.1016/j.critrevonc.2025.104748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2025] [Revised: 04/22/2025] [Accepted: 04/25/2025] [Indexed: 05/07/2025]  Open
13
Pretzsch E, Peschel CA, Rokavec M, Torlot L, Li P, Hermeking H, Werner J, Klauschen F, Neumann J, Jung A, Kumbrink J. Five-Gene Expression Signature Associated With Acquired FOLFIRI Resistance and Survival in Metastatic Colorectal Cancer. J Transl Med 2025;105:104107. [PMID: 39954853 DOI: 10.1016/j.labinv.2025.104107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2024] [Revised: 01/25/2025] [Accepted: 02/06/2025] [Indexed: 02/17/2025]  Open
14
Xie H, Sun L, Yao S, Tian X, Jin L, Dai Y, Li Y, Li Y, Fang J, Guo P, Zhang Y. Therapeutically targeting endometrial cancer in preclinical models by ICAM1 antibody-drug conjugates. Gynecol Oncol 2025;196:16-27. [PMID: 40147093 DOI: 10.1016/j.ygyno.2025.03.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2025] [Revised: 03/16/2025] [Accepted: 03/18/2025] [Indexed: 03/29/2025]
15
Wang M, Ma Q, Suthe SR, Hudson RE, Pan JY, Mikelis C, Zhu MJ, Wu ZG, Shi DR, Yao HP. Humanized dual-targeting antibody-drug conjugates specific to MET and RON receptors as a pharmaceutical strategy for the treatment of cancers exhibiting phenotypic heterogeneity. Acta Pharmacol Sin 2025;46:1375-1389. [PMID: 39837982 PMCID: PMC12032285 DOI: 10.1038/s41401-024-01458-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/13/2024] [Accepted: 12/12/2024] [Indexed: 01/23/2025]
16
Wang Z, Hong H. Anti‑HER2‑targeted therapies for the treatment of advanced HER2‑positive breast cancer with brain metastases (Review). Mol Clin Oncol 2025;22:45. [PMID: 40170686 PMCID: PMC11959222 DOI: 10.3892/mco.2025.2840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2024] [Accepted: 02/17/2025] [Indexed: 04/03/2025]  Open
17
Greenman M, Demirkiran C, Bellone S, Hartwich TM, McNamara B, Ettorre VM, Santin NG, Sethi N, Yang-Hartwich Y, Papatla K, Ratner E, Santin AD. Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma. CANCER RESEARCH COMMUNICATIONS 2025;5:774-782. [PMID: 40299780 PMCID: PMC12062949 DOI: 10.1158/2767-9764.crc-25-0057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/30/2025] [Revised: 03/27/2025] [Accepted: 04/23/2025] [Indexed: 05/01/2025]
18
Bukhalid RA, Duvall JR, Lancaster K, Catcott KC, Malli Cetinbas N, Monnell T, Routhier C, Thomas JD, Bentley KW, Collins SD, Ditty E, Eitas TK, Kelleher EW, Shaw P, Soomer-James J, Ter-Ovanesyan E, Xu L, Zurita J, Toader D, Damelin M, Lowinger TB. XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells. Clin Cancer Res 2025;31:1766-1782. [PMID: 40029253 PMCID: PMC12010966 DOI: 10.1158/1078-0432.ccr-24-2449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2024] [Revised: 09/24/2024] [Accepted: 02/19/2025] [Indexed: 03/05/2025]
19
Yaacobi Peretz S, Kessner R, Bar Y, Sonnenblick A, Lerner S, Deutsch-Lukatsky A, Popuri K, Beg MF, Shachar SS. Body composition metrics as a determinant of trastuzumab deruxtecan related toxicity and response. NPJ Breast Cancer 2025;11:38. [PMID: 40281028 PMCID: PMC12032009 DOI: 10.1038/s41523-025-00754-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2024] [Accepted: 04/09/2025] [Indexed: 04/29/2025]  Open
20
Fukuda K, Osumi H, Shimozaki K, Chin K, Ogura M, Fukuoka S, Udagawa S, Yoshino K, Tamba M, Wakatsuki T, Shinozaki E, Yamaguchi K, Ooki A. Impact of early tumor shrinkage on survival outcomes in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan in third- or later-line settings. Therap Adv Gastroenterol 2025;18:17562848251333538. [PMID: 40297207 PMCID: PMC12035244 DOI: 10.1177/17562848251333538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2024] [Accepted: 03/24/2025] [Indexed: 04/30/2025]  Open
21
Vincken R, Armendáriz-Martínez U, Ruiz-Sáenz A. ADCC: the rock band led by therapeutic antibodies, tumor and immune cells. Front Immunol 2025;16:1548292. [PMID: 40308580 PMCID: PMC12040827 DOI: 10.3389/fimmu.2025.1548292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2024] [Accepted: 03/27/2025] [Indexed: 05/02/2025]  Open
22
Lee H, Ryu JM, Lee SK, Chae BJ, Yu J, Lee JE, Kim SW, Nam SJ, Cho YA, Cho EY. HER2 mRNA Score From Quantitative ERBB2 mRNA Expression of Oncotype Dx : Can It Replace the HER2 Immunohistochemistry? Am J Surg Pathol 2025:00000478-990000000-00499. [PMID: 40170597 DOI: 10.1097/pas.0000000000002396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2025]
23
Han J, Zhai X, Tao X, Li Y, Zhao Z, Yu Z, Dong D, Yang S, Lv L. Pharmacovigilance study of adverse reactions of anti-HER-2 drugs for the treatment of HER-2-positive breast cancer based on the FAERS database. Breast Cancer Res 2025;27:54. [PMID: 40205546 PMCID: PMC11983758 DOI: 10.1186/s13058-025-02013-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2024] [Accepted: 03/29/2025] [Indexed: 04/11/2025]  Open
24
Yin Q, Zhang Y, Xie X, Hou M, Chen X, Ding J. Navigating the future of gastric cancer treatment: a review on the impact of antibody-drug conjugates. Cell Death Discov 2025;11:144. [PMID: 40188055 PMCID: PMC11972320 DOI: 10.1038/s41420-025-02429-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2024] [Revised: 03/07/2025] [Accepted: 03/21/2025] [Indexed: 04/07/2025]  Open
25
Wróbel A, Vandenberghe M, Scott M, Jones F, Matsuo T, Boothman AM, Whiteley J, Barker C. Accuracy of human epidermal growth factor receptor 2 (HER2) immunohistochemistry scoring by pathologists in breast cancer, including the HER2-low cutoff : HER2 IHC scoring concordance in breast cancer. Diagn Pathol 2025;20:35. [PMID: 40186179 PMCID: PMC11969812 DOI: 10.1186/s13000-025-01624-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2025] [Accepted: 02/26/2025] [Indexed: 04/07/2025]  Open
26
Wen L, Zhang Y, Sun C, Wang SS, Gong Y, Jia C, Luo J. Fundamental properties and principal areas of focus in antibody-drug conjugates formulation development. Antib Ther 2025;8:99-110. [PMID: 40177644 PMCID: PMC11959695 DOI: 10.1093/abt/tbaf005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2024] [Revised: 02/18/2025] [Accepted: 02/26/2025] [Indexed: 04/05/2025]  Open
27
Park YH, Bianchini G, Cortés J, Licata L, Vidal M, Iihara H, Roeland EJ, Jordan K, Scotté F, Schwartzberg L, Navari RM, Aapro M, Rugo HS. Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates. Future Oncol 2025;21:1261-1272. [PMID: 40105595 PMCID: PMC11988240 DOI: 10.1080/14796694.2025.2479417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2024] [Accepted: 03/11/2025] [Indexed: 03/20/2025]  Open
28
Theocharopoulos C, Ziogas IA, Mungo B, Gogas H, Ziogas DC, Kontis E. HER2-targeted therapies: Unraveling their role in biliary tract cancers. Crit Rev Oncol Hematol 2025;208:104655. [PMID: 39923923 DOI: 10.1016/j.critrevonc.2025.104655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2024] [Revised: 01/31/2025] [Accepted: 02/05/2025] [Indexed: 02/11/2025]  Open
29
Debbi K, Benderra MA, Medioni J, Durdux C, To NH, Boukhobza C, Grellier N, Benmaziane A, Monnier L, Gligorov J, Assaf E, Belkacemi Y. Safety and efficacy of combined trastuzumab-deruxtecan and concurrent radiation therapy in breast cancer. The TENDANCE multicentric French study. Breast 2025;80:104421. [PMID: 39983437 PMCID: PMC11893322 DOI: 10.1016/j.breast.2025.104421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2024] [Revised: 02/02/2025] [Accepted: 02/13/2025] [Indexed: 02/23/2025]  Open
30
Ahvati H, Roudi R, Sobhani N, Safari F. CD47 as a potent target in cancer immunotherapy: A review. Biochim Biophys Acta Rev Cancer 2025;1880:189294. [PMID: 40057140 DOI: 10.1016/j.bbcan.2025.189294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2024] [Revised: 02/22/2025] [Accepted: 03/02/2025] [Indexed: 03/22/2025]
31
Lee EK, Kolin DL, Matulonis UA, Erickson BK. Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers. Gynecol Oncol 2025;195:152-164. [PMID: 40117942 DOI: 10.1016/j.ygyno.2025.03.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2024] [Revised: 02/21/2025] [Accepted: 03/06/2025] [Indexed: 03/23/2025]
32
Li Z, Wang Y, Sun Y, Wang L, Li X, Sun L, He Z, Yang H, Wang Y, Wang Q, Song Z, Hong W, Wang Y, Xia G, Yu Y, Peng M, Song Y, Wang D, Meng R, Fang J, Luo Y, Liang W, Hu S, Wang Z, Song K, Li Y, Yang L, Shi W, Lu S. Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study. Lancet Oncol 2025;26:437-446. [PMID: 40020696 DOI: 10.1016/s1470-2045(25)00012-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2024] [Revised: 12/19/2024] [Accepted: 01/14/2025] [Indexed: 03/03/2025]
33
Ding M, Chen M, Cheng Z, Jin J, Lu W, Zhu S. Comparison of quaternary ammonium-based linkers for antibody-drug conjugates based on camptothecin derivatives. Bioorg Med Chem 2025;120:118084. [PMID: 39893760 DOI: 10.1016/j.bmc.2025.118084] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2024] [Revised: 01/17/2025] [Accepted: 01/22/2025] [Indexed: 02/04/2025]
34
Riudavets M, Planchard D. The Era of Antibody Drug Conjugates in Lung Cancer: Trick or Threat? Cancer Res Treat 2025;57:293-311. [PMID: 39608345 PMCID: PMC12016829 DOI: 10.4143/crt.2024.714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2024] [Accepted: 11/27/2024] [Indexed: 11/30/2024]  Open
35
Li N, Yang L, Zhao Z, Du T, Liang G, Li N, Tang J. Antibody-drug conjugates in breast cancer: current evidence and future directions. Exp Hematol Oncol 2025;14:41. [PMID: 40114224 PMCID: PMC11924693 DOI: 10.1186/s40164-025-00632-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2024] [Accepted: 03/04/2025] [Indexed: 03/22/2025]  Open
36
Wang T, Quijada D, Ahmedna T, Castillo JR, Naji NS, Peske JD, Karakousis PC, Paul S, Karantanos T, Karanika S. Targeting CCRL2 enhances therapeutic outcomes in a tuberculosis mouse model. Front Immunol 2025;16:1501329. [PMID: 40181978 PMCID: PMC11965133 DOI: 10.3389/fimmu.2025.1501329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2024] [Accepted: 02/28/2025] [Indexed: 04/05/2025]  Open
37
Qin Q. Advances in research and current challenges in the treatment of advanced HER2-low breast cancer. Front Cell Dev Biol 2025;13:1451471. [PMID: 40177129 PMCID: PMC11962219 DOI: 10.3389/fcell.2025.1451471] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2024] [Accepted: 02/20/2025] [Indexed: 04/05/2025]  Open
38
Wharton T, Spring DR. Advances in the Release of Amide-Containing Molecules. Chemistry 2025;31:e202404413. [PMID: 39836098 PMCID: PMC11914939 DOI: 10.1002/chem.202404413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2024] [Revised: 01/21/2025] [Accepted: 01/21/2025] [Indexed: 01/22/2025]
39
Andriollo P, di Mascio D, Jackson PJM, Hasan MM, Pysz-Hosey I, Procopiou G, Fox KR, Rahman KM, Thurston DE. A novel DNA sequence-selective, guanine mono-alkylating ADC payload suitable for solid tumour treatment. RSC Med Chem 2025:d4md01040j. [PMID: 40352674 PMCID: PMC12059774 DOI: 10.1039/d4md01040j] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2024] [Accepted: 03/01/2025] [Indexed: 05/14/2025]  Open
40
Larose ÉA, Hua X, Yu S, Pillai AT, Yi Z, Yu H. Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing. CANCER DRUG RESISTANCE (ALHAMBRA, CALIF.) 2025;8:11. [PMID: 40201309 PMCID: PMC11977375 DOI: 10.20517/cdr.2024.180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/11/2024] [Revised: 02/17/2025] [Accepted: 02/28/2025] [Indexed: 04/10/2025]
41
Xie J, Yang Z, Li Z, Zhang T, Chen H, Chen X, Dai Z, Chen T, Hou J. Triple-positive breast cancer: navigating heterogeneity and advancing multimodal therapies for improving patient outcomes. Cancer Cell Int 2025;25:77. [PMID: 40045297 PMCID: PMC11881339 DOI: 10.1186/s12935-025-03680-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2024] [Accepted: 02/07/2025] [Indexed: 03/09/2025]  Open
42
Masmudi-Martín M, Oller-Salvia B, Perea M, Teixidó M, Valiente M, Giralt E, Sánchez-Navarro M. A Site-Specific MiniAp4-Trastuzumab Conjugate Prevents Brain Metastasis. Mol Pharm 2025;22:1384-1395. [PMID: 39924896 PMCID: PMC11881140 DOI: 10.1021/acs.molpharmaceut.4c01091] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2024] [Revised: 01/22/2025] [Accepted: 01/23/2025] [Indexed: 02/11/2025]
43
Sloot WN, Bertotti E, Onidi M, Paoletti A, Salve ID, Tavano P, Vigna E, Mueller G. The Nonclinical Safety Assessment of a Novel Anti-CEACAM5 Antibody Exatecan Conjugate Predicts a Low Risk for Interstitial Lung Disease (ILD) in Patients-The Putative Mechanism Behind ILD. Int J Toxicol 2025;44:153-169. [PMID: 39754485 DOI: 10.1177/10915818241306039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2025]
44
Pourjamal N, Le Joncour V, Vereb G, Honkamaki C, Isola J, Leyton JV, Laakkonen P, Joensuu H, Barok M. Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan. Transl Oncol 2025;53:102284. [PMID: 39837059 PMCID: PMC11788861 DOI: 10.1016/j.tranon.2025.102284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2024] [Revised: 12/27/2024] [Accepted: 01/13/2025] [Indexed: 01/23/2025]  Open
45
Yamazaki S, Matsuda Y. Antibody Modification via Lipoic Acid Ligase A-Mediated Site-Specific Labeling. Chem Biodivers 2025;22:e202402113. [PMID: 39435640 DOI: 10.1002/cbdv.202402113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2024] [Revised: 10/19/2024] [Accepted: 10/21/2024] [Indexed: 10/23/2024]
46
Ellis H, Braconi C, Valle JW, Bardeesy N. Cholangiocarcinoma Targeted Therapies: Mechanisms of Action and Resistance. THE AMERICAN JOURNAL OF PATHOLOGY 2025;195:437-452. [PMID: 39730074 PMCID: PMC11841491 DOI: 10.1016/j.ajpath.2024.11.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/12/2024] [Revised: 11/18/2024] [Accepted: 11/25/2024] [Indexed: 12/29/2024]
47
Farhat J, Sakai H, Tsurutani J. Management of nausea and vomiting induced by antibody-drug conjugates. Breast Cancer 2025;32:278-285. [PMID: 39878905 PMCID: PMC11842424 DOI: 10.1007/s12282-025-01670-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2024] [Accepted: 01/18/2025] [Indexed: 01/31/2025]
48
Zhou L, Zhang Y, Zhang J, Wang H, Zhao B, Cai Y, Qu Y, Li X, Zhang D. Clinical characteristics and therapeutic direction of HER2 low-expression breast cancer. Front Oncol 2025;15:1484103. [PMID: 40083869 PMCID: PMC11903420 DOI: 10.3389/fonc.2025.1484103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2024] [Accepted: 01/31/2025] [Indexed: 03/16/2025]  Open
49
Dennis N, Dunton K, Livings C, Bogoeva N, Bourke S, Oluboyede Y, Hamilton E, Iwata H, Cortés J. Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial. Eur J Cancer 2025;217:115192. [PMID: 39798264 DOI: 10.1016/j.ejca.2024.115192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2024] [Revised: 11/25/2024] [Accepted: 12/10/2024] [Indexed: 01/15/2025]
50
Yamanaka T, Nishikawa T, Yoshida H. Development of Antibody-Drug Conjugates for Malignancies of the Uterine Corpus: A Review. Cells 2025;14:333. [PMID: 40072062 PMCID: PMC11898814 DOI: 10.3390/cells14050333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2025] [Revised: 02/17/2025] [Accepted: 02/21/2025] [Indexed: 03/15/2025]  Open
PrevPage 1 of 15 123451415Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Excel